Annual report pursuant to Section 13 and 15(d)

Revenue (Tables)

v3.8.0.1
Revenue (Tables)
12 Months Ended
Dec. 31, 2017
Revenue from Contract with Customer [Abstract]  
Revenue
During the years ended December 31, 2017 and 2016, respectively, the Company recognized revenues as follows (in thousands):
 
Years Ended December 31,
 
2017
 
2016
License fees
$
11,285

 
$
2,736

Research and development services
1,403

 
1,440

Milestone payments
12,573

 
1,655

Other revenues
14

 

Total Revenue
$
25,275

 
$
5,831


During the years ended December 31, 2017 and 2016, respectively, the Company recognized revenue from the following strategic partnerships and other license agreements (in thousands):
 
Years Ended December 31,
 
2017
 
2016
AstraZeneca
$
19,769

 
$

Servier
1,907

 

Roche
3,516

 
4,080

Other
83

 
1,751

Total Revenue
$
25,275

 
$
5,831

Potential Milestone Payments
Under the Company´s existing strategic partnerships and other license agreements, Pieris could receive the following potential milestone payments (in millions):
 
Research, Development & Regulatory Milestones
 
Sales Milestones
AstraZeneca
$
1,111

 
$
960

Servier
1,040

 
942

Roche
290

 
123

Other
68

 

Total potential milestone payments
$
2,509

 
$
2,025